Study of Parkinson's Early Stage With Deferiprone

Inclusion Criteria

• •Male or female aged ≥18 to \< 80 years
• •Body weight ≥60 kg but ≤100 kg
• •Parkinson's disease diagnosed
• •Absolute neutrophil count (ANC) ≥1.5 x 10\^9/L (≥1.0 x 10\^9/L for Black population) at screening
• •On a stable dose for at least 3 months prior to the screening visit of any of the following treatments at an L-dopa equivalent daily dose of up to 600 mg:
• •Dopaminergic agonist alone
• •L-dopa alone
• •Combination therapy with dopaminergic agonist and L-dopa
• •Rasagiline
• •At an early stage of the disease, without motor fluctuations and/or L-dopa-induced dyskinesia
• •Current treatment with coenzyme Q10 or idebenone. (Patients who are on these medications but stop taking them at least 2 weeks prior to baseline may be enrolled.)
• •Current use of a Deep Brain Stimulation (DBS) system. (Patients who previously had a DBS system but have had it removed may be enrolled.)